Able Sciences
RNA-based off-the-shelf immune cells for therapies.
Able Sciences, Inc. is a biotechnology company founded in 2023 and based in Princeton, New Jersey, that develops cell engineering technology. The company was co-founded by Jolly Mazumdar, who serves as CEO, and Thimmaiah Chendrimada, the Chief Scientific Officer. Mazumdar has over 14 years of experience in drug discovery and development, having previously worked at GSK and founded Chimeron Bio, an RNA-focused biotech firm.
The company is focused on deploying an RNA technology platform to create off-the-shelf, cost-effective cell therapies. Its primary focus is on developing allogeneic Natural Killer (NK) cells to treat solid cancers and autoimmune disorders. The technology aims to express multiple kill signals in cell therapy in a single step, offering a multivalent approach that turns a single treatment into a combination therapy.
Able Sciences operates within the biotechnology and therapeutics sectors. The firm's business model is centered on the research and development of its proprietary RNA platform to create disease-fighting cells, with the goal of enabling healthcare and biotechnology sectors to develop more effective treatments. As a seed-stage startup, the company has secured funding from investors including SOSV and IndieBio.
Keywords: RNA technology, cell therapy, allogeneic NK cells, solid cancers, autoimmune disorders, cell engineering, off-the-shelf therapies, immunotherapy, biopharmaceutical, oncology, drug discovery, therapeutics, biotechnology